The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KZR | -17.82% | -88.82% | -35.46% | -97% |
| S&P | +13.19% | +87.83% | +13.42% | +145% |
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.23M | 12.7% |
| Market Cap | $28.56M | -49.4% |
| Market Cap / Employee | $0.52M | 0.0% |
| Employees | 55 | -5.2% |
| Net Income | -$11.23M | 44.7% |
| EBITDA | -$11.49M | 47.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $38.94M | 11.7% |
| Accounts Receivable | $1.74M | 248.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.37M | -85.7% |
| Short Term Debt | $8.54M | 16.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -47.14% | -0.8% |
| Return On Invested Capital | -39.16% | -5.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.83M | 43.9% |
| Operating Free Cash Flow | -$9.83M | 43.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.37 | 0.30 | 0.32 | 0.31 | -26.12% |
| Price to Sales | 9.84 | 9.38 | 6.24 | - | |
| Price to Tangible Book Value | 0.37 | 0.30 | 0.32 | 0.31 | -91.69% |
| Enterprise Value to EBITDA | 3.14 | 3.72 | 3.85 | 4.50 | 30.14% |
| Return on Equity | -55.0% | -57.8% | -58.4% | -56.9% | 3.91% |
| Total Debt | $16.18M | $14.11M | $12.07M | $9.91M | -41.39% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
